SIBN SI-BONE

SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance

SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance
EN
08/10/2020

Underlying

SIBNSI-BONE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SI-BONE

 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on M...

SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026 SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time. Investors interested in listening to the conference call ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results ...

SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026 SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the...

February 2, 2026 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full ...

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025 Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2025. Fourth Quarter 2025 Summary (any comparisons are to the prior year period) Worldwide revenue ...

January 12, 2026 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference ...

SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, December 2, 2025, at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this...

November 18, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and...

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.7 million, representing growth of 20.6%  U.S. revenue of $46.4 million, representing growth of 21.2%Gross margin of 79.8%, representing an improvement of 75 basis pointsNet loss of $4.6 million, representing an improvement of 30.6%  Positive adjusted EBITDA of $...

November 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch